Froniglutide is under clinical development by ImmunoForge and currently in Phase II for Dermatomyositis. According to GlobalData, Phase II drugs for Dermatomyositis have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Froniglutide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Froniglutide overview
Froniglutide is under development for the treatment of Duchenne muscular dystrophy, polymyositis, dermatomyositis, senile sarcopenia and inclusion body myositis (IBM). It is administered through subcutaneous route. The drug candidate is a long-acting glucagon like peptide-1 (GLP-1) elastin like peptide (ELP)-120 fusion protein which acts by targeting glucagon-like peptide 1 receptor (GLP1R).
The drug candidate was under development for the treatment of hyperglycemia associated with type 2 diabetes and Becker muscular dystrophy.
For a complete picture of Froniglutide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
